Linda Greub
Managing Partner at Avestria Ventures
San Francisco Bay Area
Overview
Work Experience
Board Member
2024 - Current
Managing Partner
2018
Investing in Early Stage Women's Health and Life Science Ventures
Avestria Ventures is an investment firm that focuses on women's health and female-led life science and healthcare companies.
Member Board Of Directors
2022
Board Observer
2019
Raydiant Oximetry is a medical device company focused on improving outcomes for mothers and babies during childbirth.
Raised $25,574,392.00 from V-Capital, Global Health Impact Fund, March of Dimes, Cross-Border Impact Ventures, RH Capital, Tri-Valley Ventures, SteelSky Ventures, Band of Angels, Avestria Ventures and THE CATALYTIC IMPACT FOUNDATION (CIF).
Board Observer
2021
CEO
2016 - 2018
Life science consulting & financial advisory.
Partner
2010 - 2018
Provided seed capital to early stage companies in Life Science, Education and the Consumer Sector.
VP Corporate Development
2015 - 2016
Led partnership outreach for NGS sample enrichment technology company focused on liquid biopsy for early detection & monitoring of cancer, inherited & infectious disease. Acquired by Bio-Rad.
RainDance Technologies develops medical technology solutions.
Raised $164,439,839.00 from GE Ventures, Northgate Capital, Alloy Ventures, Sectoral Asset Management, Myriad Genetics, Quaker BioVentures, Acadia Woods Partners and Mohr Davidow Ventures.
VP Strategy & Corporate Development
2013 - 2014
Redefined corporate strategy for ultra-sensitive protein detection technology company focused on cardiovascular disease and led efforts to sell RUO business unit.
Director Diagnostics Strategy, Business Development and M&A
2011 - 2013
Led molecular diagnostics M&A efforts within the $3B Vaccines & Infectious Disease Diagnostics Division of Novartis AG.